Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: Relevance for bipolar disorder
Adriano José Maia Chaves Filho, Natássia Lopes Cunha, Alana Gomes de Souza, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 99, pp. 109872-109872
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Mette Kruse Klausen, Morgane Thomsen, Gitta Wörtwein, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 625-641
Open Access | Times Cited: 110
Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol
Candan Yasemin Eren, Arya Yigit, Ramazan Efe Dogruoz, et al.
Frontiers in Behavioral Neuroscience (2021) Vol. 14
Open Access | Times Cited: 72
Clinical insights into the cross-link between mood disorders and type 2 diabetes: A review of longitudinal studies and Mendelian randomisation analyses
Chiara Possidente, Giuseppe Fanelli, Alessandro Serretti, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 152, pp. 105298-105298
Open Access | Times Cited: 35
IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns, Elizabeth H. Tressler, Leandro F. Vendruscolo, et al.
Pharmacological Research (2024) Vol. 207, pp. 107312-107312
Open Access | Times Cited: 10
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access | Times Cited: 1
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Silvia Tempia Valenta, Alba Nicastri, Federica Perazza, et al.
Current Treatment Options in Psychiatry (2024)
Closed Access | Times Cited: 6
GLP-1 agonist Liraglutide prevents MK‑801–induced schizophrenia‑like behaviors and BDNF, CREB, p-CREB, Trk-B expressions in the hippocampus and prefrontal cortex in Balb/c mice
Meltem Dönmez Kutlu, Seda Köse, Kübra Akıllıoğlu
Behavioural Brain Research (2023) Vol. 445, pp. 114386-114386
Closed Access | Times Cited: 16
Gut Microbial Dysbiosis and Cognitive Impairment in Bipolar Disorder: Current Evidence
Wenyu Dai, Jieyu Liu, Qiu Yan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 22
Serum Asprosin and Peptide Tyrosine Tyrosine (PYY) Levels in Bipolar Disorder
Nilifer Gürbüzer, Elif Özcan Tozoğlu, Alev Lazoğlu Özkaya, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 1012-1012
Open Access
One Size Does Not Fit All: Special Considerations for Behavioral Health Providers Treating Patients Using GLP-1RA Medications for Obesity
Noreen A. Reilly-Harrington, Susan Himes, Jennifer Lauretti-Robbins, et al.
Cognitive and Behavioral Practice (2025)
Closed Access
Neurobehavioral and molecular changes in rats exposed to either captagon or counterfeit captagon
Yusuf S. Althobaiti, Areej Hamed AL-Shanbari, Doaa S. Alshoaibi, et al.
Saudi Pharmaceutical Journal (2025) Vol. 33, Iss. 1-2
Open Access
Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson’s Disease Mouse Model
Zijuan Zhang, Hai Li, Yunfang Su, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 18
Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study
Xiang Lin, Ying Peng
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2741-2741
Open Access
Doxycycline reverses cognitive impairment, neuroinflammation and oxidative imbalance induced by D-amphetamine mania model in mice: A promising drug repurposing for bipolar disorder treatment?
Adriano José Maia Chaves Filho, Natássia Lopes Cunha, Patrícia de Araújo Rodrigues, et al.
European Neuropsychopharmacology (2020) Vol. 42, pp. 57-74
Closed Access | Times Cited: 21
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential
Jonathan Martin Flintoff, James P. Kesby, Dan Siskind, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 8, pp. 877-891
Closed Access | Times Cited: 18
Anti-stress effects of the glucagon-like peptide-1 receptor agonist liraglutide in zebrafish
Pablo Ricardo Bertelli, Ricieri Mocelin, Matheus Marcon, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2021) Vol. 111, pp. 110388-110388
Open Access | Times Cited: 18
Chronic lithium treatment ameliorates ketamine-induced mania-like behavior via the PI3K-AKT signaling pathway
Rong‐Jun Ni, Tian-Hao Gao, Yiyan Wang, et al.
动物学研究 (2022) Vol. 43, Iss. 6, pp. 989-1004
Open Access | Times Cited: 12
Baicalein: A potential GLP-1R agonist improves cognitive disorder of diabetes through mitophagy enhancement
Na Liu, Xin Cui, Wenhui Yan, et al.
Journal of Pharmaceutical Analysis (2024) Vol. 14, Iss. 8, pp. 100968-100968
Open Access | Times Cited: 2
Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation
Haoqiang Zhang, Yafen Chu, Hongwei Zheng, et al.
Aging (2020) Vol. 13, Iss. 1, pp. 525-536
Open Access | Times Cited: 17
GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state via GSK-3β pathway
Mustafa Nusret Çiçekli, Emre Soner Tiryaki, Ahmet Altun, et al.
Journal of Receptors and Signal Transduction (2022) Vol. 42, Iss. 5, pp. 486-494
Closed Access | Times Cited: 10
Chronic lithium exposure attenuates ketamine-induced mania-like behavior and c-Fos expression in the forebrain of mice
Tian-Hao Gao, Rong‐Jun Ni, Shasha Liu, et al.
Pharmacology Biochemistry and Behavior (2021) Vol. 202, pp. 173108-173108
Closed Access | Times Cited: 14
Quercetin relieves D‐amphetamine‐induced manic‐like behaviour through activating TREK‐1 potassium channels in mice
Keke Ren, Haiying Liu, Baolin Guo, et al.
British Journal of Pharmacology (2021) Vol. 178, Iss. 18, pp. 3682-3695
Open Access | Times Cited: 8
A neurocognitive perspective on the relationship between exercise and reward: Implications for weight management and drug addiction
Yu Zhou, R. James Stubbs, Graham Finlayson
Appetite (2022) Vol. 182, pp. 106446-106446
Open Access | Times Cited: 5
GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner
Taylor S. Trammell, Natalie Lynn Henderson, Haley S. Madkour, et al.
Neurological Sciences (2020)
Open Access | Times Cited: 7
Doxycycline reversal of amphetamine-induced mania-like behavior is related to adjusting brain monoamine abnormalities and antioxidant effects in primary hippocampal neurons
Adriano José Maia Chaves-Filho, Michele Verde-Ramo Soares, Paloma Marinho Jucá, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 8, pp. 6017-6035
Open Access
Page 1 - Next Page

Scroll to top